DELRAY BEACH, Fla.-- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced that it has signed a Space Act Agreement with NASA's Ames Research Center to collaborate on testing the Company's Firefly Dx detection system ("Firefly") as a platform for biological research and commercial development for ground and space applications. 

PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan® PCR (polymerase chain reaction) chemistry. Firefly is intended to derive results from a sample in less than 20 minutes at the point of need, compared to two to four hours for a lab device. Quicker, accurate diagnostics derived from Firefly may lead to more rapid and effective treatment than what is currently available with existing systems. Firefly is being developed to meet the growing need for more rapid and accurate point-of-need diagnostics that will enable hospitals, first responders, and other providers to save lives. 

Under this Space Act Agreement, NASA will assess the Company's Firefly Dx technology for potential ground and space applications, while PositiveID will assess the technology to improve its development of the Firefly Dx hardware for extreme environments, such as Department of Defense field applications. 

William J. Caragol, Chairman and CEO of PositiveID, said, "We are very proud to collaborate with NASA's world- team of scientists and researchers on the continued development of Firefly to advance mission-critical applications for point-of-need diagnostics, both in space and on the front lines to protect our nation from future bioterrorism threats." 

About PositiveID Corporation  PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com. 

For more information, contact: Allison Tomek PostiveID Corporation Phone: 561-805-8000 Email: atomek@positiveidcorp.com